The Board of Directors of Occlutech Holding AG[1] (“Occlutech” or the “Company”) has today decided to withdraw the contemplated IPO, and thereby withdraw (i) the offering to acquire Swedish Depository Receipts (“SDRs”) and (ii) the Company's application for admission to trading of the SDRs on Nasdaq First North Premier Growth Market.
The prospectus relating to Occlutech’s offering to acquire SDRs and the Company’s application for admission to trading of the SDRs on Nasdaq First North Premier Growth Market was published by the Company on September 16, 2021.
Occlutech’s products and market potential has met a strong interest from investors both in Sweden and internationally. The Company’s contemplated IPO was also committed by reputable cornerstone investors.
Despite the fact that the indicated demand exceeded the number of SDRs offered, with an oversubscribed offering, the demand from long-term investors in the offering, in combination with the weak MedTech sector sentiment, was not considered strong enough to ensure a satisfactory trading in the SDRs after the IPO.
As a result, Occlutech’s Board of Directors has today decided to withdraw the contemplated IPO.
For more information, please contact:
Sabine Bois
CEO
Email: sabine.bois@occlutech.com
Phone: +49 160 90792130
[1] Occlutech Holding AG is a Swiss limited liability company.
About Occlutech
Occlutech is a leading specialist provider of minimally invasive cardiac devices, with a mission to improve the quality of life for people with heart conditions. The vision is to become a global leading specialist provider in cardiac devices, addressing congenital heart defects, stroke prevention and heart failure. Occlutech has a broad and proven portfolio, based on proprietary technology, and over 200 patents with more than 134,000 products sold. The company markets and sells its products in circa 85 countries and has around 250 employees. Occlutech is a public limited liability company registered in Switzerland. For more information visit www.occlutech.com.